Investor Relations

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

View company overview

Recent earnings

View all

Events

Event

Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026 1:00 PM EDT
Learn more
Event

Leerink Global Healthcare Conference

Mar 9, 2026 8:00 AM EDT
Learn more
Event

TD Cowen 46th Annual Health Care Conference

Mar 3, 2026 3:10 PM EST
Learn more
Event

Certara Fourth Quarter 2025 Earnings Conference Call

Feb 26, 2026 8:30 AM EST
Learn more

News releases

View all
Mar 03, 2026
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.  RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp ®

Read more
Feb 27, 2026
Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: TD Cowen 46 th Annual Health Care Conference Date and Time: Tuesday, March

Read more
Feb 26, 2026
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance

FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb.

Read more